Genzyme shareholders urged to vote for Icahn nominees, but Campath could be snag
This article was originally published in Scrip
Executive Summary
Carl Icahn has again criticised Genzyme in the ongoing battle for control over the beleaguered biotech, saying that the firm's "inability to fully manufacture and supply certain of its products leads to the conclusion that the manufacturing system at Genzyme is broken".